A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease

Transplantation

Volumn 62, Issue 5, 1996, Pages 626-631

  Mccarthy Jr , Philip L ^a,b   Williams, Lori ^a   Harris Bacile, Margaret ^a   Yen, Josephine ^a   Przepiorka, Donna ^c   Ippoliti, Cindy ^c   Champlin, Richard ^c   Fay, Joseph ^d   Blosch, Consuelo ^e   Jacobs, Cindy ^e,f   Anasetti, Claudio ^g  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e AMGEN INC   (United States)

^f Cell Pro Inc   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD3; RECOMBINANT INTERLEUKIN 1; THIOTEPA; XOMAZYME;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RESISTANCE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 9544224248     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609150-00015     Document Type: Article

References (36)

1. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44: 153.
2. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1260.
3. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 1990; 75: 1011.
4. McCarthy PL Jr, Abhyankar S, Neben S, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915.
5. Smith SR, Terminelli C, Kenworthy-Bott L, Phillips DL. A study of cytokine production in acute graft-versus-host disease. Cell Immunol 1991; 134: 336.
6. Symington FW, Symington BE, Liu PY, Viguet H, Santhanam U, Sehgal PB. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992; 54: 457.
7. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol 1993; 23: 333.
8. Tanaka J, Imamura M, Kasai M, et al. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 1993; 85: 558.
9. Chasty RC, Lamb WR, Gallati H, Roberts TE, Brenchley PEC, Liu Yin JA. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993; 12: 331.
10. Wall DA, Sheehan KCF. The role of tumor necrosis factor and interferon-γ in graft-versus-host disease and related immunodeficiency. Transplantation 1994; 57: 273.
11. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362.
12. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of glucocorticoid-resistant graft-versus-host disease. Blood 1994; 84: 1342.
13. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167.
14. Sims JE, Giri JG, Dower SK. The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 1994; 72: 9.
15. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 1991; 338: 1423.
16. Sims JE, March CJ, Cosman D, et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988; 241: 585.
17. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261: 472.
18. Slack J, McMahan CJ, Waugh S, et al. Independent binding of interleukin-1α and interleukin-1β to type I and type II interleukin-1 receptors. J Biol Chem 1993; 268: 2513.
19. Dower SK, Wignall JM, Schooley K, et al. Retention of ligand binding activity by the extracellular domain of the IL-1 receptor. J Immunol 1989; 142: 4314.
20. Mullarkey MF, Leiferman KM, Peters MS, et al. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 1994; 152: 2033.
21. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 895.
22. Storb R, Thomas ED, Buckner RA, et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood 1974; 43: 157.
23. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1987; 70: 1382.
24. Thomas ED, Storb R, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 1982; 8: 817.
25. Przepiorka D, Ippoliti C, Giralt S, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 1994; 14: 449.
26. Forman SJ, Blume KG, Krance RA, et al. A prospective randomized study of acute graft-versus-host disease in 107 patients with leukemia: methotrexate/prednisone versus cyclosporine/ prednisone. Transplant Proc 1987; 21: 2605.
27. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325.
28. Ringden O, Kersey JH. Prevention and therapy of graft-versus-host disease. Report from a work-shop. Bone Marrow Transplant 1992; 10 (suppl 1): 22.
29. Anasetti C, Hansen JA, Waldman TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320.
30. Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophos-phoramide. J Chronic Dis 1960; 11: 7.
31. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239.
32. Sutherland HJ, Eaves AC, Eaves CJ. Quantitative assays for human hematopoietic progenitor cells. In: Gee AP, ed. Bone marrow processing and purging: a practical guide. Boca Raton, FL: CRC Press, 1991: 155.
33. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 1989; 4: 247.
34. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821.
35. Manetti R, Barak V, Piccinni MP, et al. Interleukin-1 favours the in vitro development of type 2 T helper (Th2) human T-cell clones. Res Immunol 1994; 45: 93.
36. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540.